Proteomic differential display analysis for TS-1-resistant and -sensitive pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry

Anticancer Research

Volumn 31, Issue 6, 2011, Pages 2103-2108

  Yoshida, Kanako ^a   Kuramitsu, Yasuhiro ^a   Murakami, Kohei ^a   Ryozawa, Shomei ^a   Taba, Kumiko ^a   Kaino, Seiji ^a   Zhang, Xiulian ^a   Sakaida, Isao ^a   Nakamura, Kazuyuki ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

LC MS MS; Pancreatic cancer; Proteomics; TS 1; Two dimensional gel electrophoresis

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; CHAPERONIN CONTAINING TCP1; ELONGATION FACTOR 1; ELONGATION FACTOR 1 DELTA; ENDOPLASMIN; FASCIN; FLUOROURACIL; GIMERACIL; HYPOXIA UPREGULATED PROTEIN 1; LAMIN A; LAMIN C; LIPOCORTIN 1; PEROXIREDOXIN 2; RIBONUCLEASE INHIBITOR; SUPEROXIDE DISMUTASE; TS 1; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL ASSAY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MASS SPECTROMETER; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FLUOROURACIL; HUMANS; MASS SPECTROMETRY; NEOPLASM PROTEINS; OXONIC ACID; PANCREATIC NEOPLASMS; PROTEOMICS; PYRIDINES; TEGAFUR;

EID: 79960450335     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Vital Statistics of Japan 2003, Statistics and Information Dept., Minister's Secretariat, Ministry of Health, Labor and Welfare of Japan.
2. Komoto M, Nakata B, Nishii T, Kawajiri H, Shinto O, Amano R, Yamada N, Yashiro M and Hirakawa K: In vitro and in vivo evidence that a combination of lapatinib plus S-1 is a promising treatment for pancreatic cancer. Cancer Sci 101: 468-473, 2010.
3. Nakai Y, Isayama H, Sasaki T, Sasahira N, Ito Y, Kogure H, Togawa O, Matsubara S, Arizumi T, Yagioka H, Yashima Y, Kawakubo K, Mizuno S, Yamamoto K, Hirano K, Tsujino T, Ijichi H, Tateishi K, Toda N, Tada M, Omata M and Koike K: Impact of S-1 on the survival of patients with advanced pancreatic cancer. Pancreas 39: 989-993, 2010.
4. Kuramitsu Y and Nakamura K: Current progress in proteomic study of hepatitis C virus-related human hepatocellular carcinoma. Expert Rev Proteom 2: 589-601, 2005. (Pubitemid 41139841)
5. Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, Mikuriya K, Fujimoto M, Maehara S, Maehara Y, Okita K, Nakamura K and Sakaida I: Proteomics finding heat-shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int J Oncol 31: 1345-1350, 2007.
6. Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, Taba K, Fujimoto M, Okita K, Nakamura K and Sakaida I: A proteomic profiling of gemcitabine resistance in pancreatic cancer cell lines. Mol Med Rep 1: 429-434, 2008.
7. Mori-Iwamoto S, Taba K, Kuramitsu Y, Ryozawa S, Tanaka T, Maehara S, Maehara Y, Okita K, Nakamura K and Sakaida I: Interferon-γ down-regulates HSP27 of pancreatic cancer cells, and helps the cytotoxic effect of gemcitabine. Pancreas 38: 224-226, 2009.
8. Kim WY, Nakata B and Hirakawa K: Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy. Cancer Sci 98: 1604-1608, 2007. (Pubitemid 47308458)
9. Kuramitsu Y, Taba K, Ryozawa S, Yoshida K, Tanaka T, Zhang X, Maehara S, Maehara Y, Sakaida I and Nakamura K: Identification of up- and down-regulated proteins in gemcitabine-resistant pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry. Anticancer Res 30: 3367-3372, 2010.
10. Kuramitsu Y, Miyamoto H, Tanaka T, Zhang X, Fujimoto M, Ueda K, Tanaka T, Hamano K and Nakamura K: Proteomic differential display analysis identified up-regulated astrocytic phosphoprotein PEA-15 in human malignant pleural mesothelioma cell lines. Proteomics 9: 5078-5089, 2009.
11. Tanaka T, Kuramitsu Y, Fujimoto M, Naito S, Oka M and Nakamura K: Down-regulation of two isoforms of ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCH-L1) correlates with high metastatic potentials of human SN12C renal cell carcinoma cell clones. Electrophoresis 29: 2651-2659, 2008. (Pubitemid 351911893)
12. Kuramitsu Y, Baron B, Yoshino S, Zhang X, Tanaka T, Yashiro M, Hirakawa K, Oka M and Nakamura K: Proteomic differential display analysis shows up-regulation of 14-3-3 protein sigma in human scirrhous-type gastric carcinoma cells. Anticancer Res 30: 4459-4465, 2010.
13. Kuramitsu Y, Hayashi E, Okada F, Tanaka T, Zhang X, Ueyama Y and Nakamura K: Proteomic analysis for nuclear proteins related to tumour malignant progression: a comparative proteomic study between malignant progressive cells and regressive cells. Anticancer Res 30: 2093-2099, 2010.
14. Kuramitsu Y, Hayashi E, Okada F, Zhang X, Tanaka T, Ueyama Y and Nakamura K: Staining with highly sensitive Coomassie Brilliant Blue SeePico™ stain after Flamingo™ fluorescent gel stain is useful for cancer proteomic analysis by means of two-dimensional gel electrophoresis. Anticancer Res 30: 4001-4005, 2010.
15. Zhang X, Kuramitsu Y, Fujimoto M, Hayashi E, Yuan X and Nakamura K: Proteomic analysis of macrophages stimulated by lipopolysaccharide: Lipopolysaccharide inhibits the cleavage of nucleophosmin. Electrophoresis 27: 1659-1668, 2006.
16. Kuramitsu Y, Harada T, Takashima M, Yokoyama Y, Hidaka I, Iizuka N, Toda T, Fujimoto M, Zhang X, Sakaida I, Okita K, Oka M and Nakamura K: Increased expression, and phosphorylation of liver glutamine synthetase in well-differentiated hepatocellular carcinoma tissues of patients infected with hepatitis C virus. Electrophoresis 27: 1651-1658, 2006.
17. Namba T, Hoshino T, Tanaka K, Tsutsumi S, Ishihara T, Mima S, Suzuki K, Ogawa S and Mizushima T: Up-regulation of 150-kDa oxygen-regulated protein by celecoxib in human gastric carcinoma cells. Mol Pharmacol 71: 860-870, 2007. (Pubitemid 46294098)
18. Stojadinovic A, Hooke JA, Shriver CD, Nissan A, Kovatich AJ, Kao TC, Ponniah S, Peoples GE and Moroni M: HYOU1/ ORP150 expression in breast cancer. Med Sci Monit 13: 231-239, 2007.
19. de Graauw M, van Miltenburg MH, Schmidt MK, Pont C, Lalai R, Kartopawiro J, Pardali E, Le Dévédec SE, Smit VT, van der Wal A, Van't Veer LJ, Cleton-Jansen AM, ten Dijke P and van de Water B: Annexin Al regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells. Proc Natl Acad Sci USA 107: 6340-6345, 2010.
20. Keenan J, Murphy L, Henry M, Meleady P and Clynes M: Proteomic analysis of multidrug-resistance mechanisms in adriamycin-resistant variants of DLKP, a squamous lung cancer cell line. Proteomics 9: 1556-1566, 2009.
21. Wang Y, Serfass L, Roy MO, Wong J, Bonneau AM and Georges E: Annexin-I expression modulates drug resistance in tumor cells. Biochem Biophys Res Commun 314: 565-570, 2004. (Pubitemid 38084756)
22. Hashimoto Y, Skacel M and Adams JC: Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker? Int J Biochem Cell Biol 37: 1787-1804, 2005.
23. Yamakita Y, Ono S, Matsumura F and Yamashiro S: Phosphorylation of human fascin inhibits its actin binding and bundling activities. J Biol Chem 271: 12632-12638, 1996. (Pubitemid 26163336)
24. Zheng HC, Takahashi H, Li XH, Hara T, Masuda S, Guan YF and Takano Y: Overexpression of GRP78 and GRP94 are markers for aggressive behavior and poor prognosis in gastric carcinomas. Hum Pathol 39: 1042-1049, 2008.
25. Di Michele M, Marcone S, Cicchillitti L, Della Corte A, Ferlini C, Scambia G, Donati MB and Rotilio D: Glycoproteomics of paclitaxel resistance in human epithelial ovarian cancer cell lines: towards the identification of putative biomarkers. J Proteomics 73: 879-898, 2010.
26. Boyer J, Allen WL, McLean EG, Wilson PM, McCulla A, Moore S, Longley DB, Caldas C and Johnston PG: Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res 66: 2765-2777, 2006.
27. Bacolod MD, Lin SM, Johnson SP, Bullock NS, Colvin M, Bigner DD and Friedman HS: The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide. Curr Cancer Drug Targets 8: 172-179, 2008. (Pubitemid 351666854)
28. Lee KW, Ko BC, Jiang Z, Cao D and Chung SS: Overexpression of aldose reductase in liver cancers may contribute to drug resistance. Anticancer Drugs 12: 129-132, 2001. (Pubitemid 32207361)